Peringatan Keamanan

Administration of supratherapeutic doses of exogenous oxytocin can lead to myocardial ischemia, tachycardia, and arrhythmias.A228958 High doses can also lead to uterine spasms, hypertonicity, or rupture.A228958 Oxytocin has antidiuretic properties, thus, high daily doses (as a single dose or administered slowly over 24 hours) may lead to extreme water intoxication resulting in maternal seizures, coma, and even death.A228958 The risk of antidiuresis and water intoxication in the mother appears to be greater when fluids are given orally.A228958

Oxytocin

DB00107

biotech approved vet_approved

Deskripsi

Sir Henry H. Dale first identified oxytocin and its uterine contractile properties in 1906.A229008,A228593,A229108 Like all other neurohypophysial hormones, oxytocin is composed of nine amino acids with a disulfide bridge between the Cys 1 and 6 residues.A229008,A228593 In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent du Vigneaud; he was later recognized with a Nobel prize for his work.A229108 Oxytocin continues to be an important tool in modern obstetrics to induce labor when indicated and to manage postpartum hemorrhage.A229108,A229113 It is estimated that labor induction with oxytocin is used in almost 10% of deliveries globally.A228593

It should be noted that there are risks associated with oxytocin intervention during childbirth. Oxytocin should be used judiciously only when necessary and by experienced healthcare practitioners.A229113

Although most commonly linked to labor and delivery, oxytocin actually has broad peripheral and central effects.A229008 It plays an important role in pair bonding, social cognition and functioning, and even fear conditioning.A229013 Oxytocin also serves a role in metabolic homeostasis and cardiovascular regulation.A228593,A229098

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The plasma half-life of oxytocin ranges from 1-6 minutes. The half-life is decreased in late pregnancy and during lactation.[L31433]
Volume Distribusi -
Klirens (Clearance) In a study that observed 10 women who were given oxytocin to induce labor, the mean metabolic clearance rate was 7.87 mL/min.[A229053]

Absorpsi

Oxytocin is administered parenterally and is fully bioavailable. It takes approximately 40 minutes for oxytocin to reach steady-state concentrations in the plasma after parenteral administration.L31788

Metabolisme

Oxytocin is rapidly removed from the plasma by the liver and kidney.L31433 The enzyme oxytocinase is largely responsible for the metabolism and regulation of oxytocin levels in pregnancy and only a small percentage of the neurohormone is excreted in the urine unchanged.L31433,L31788 Oxytocinase activity increases throughout pregnancy and peaks in the plasma, placenta and uterus near term.L31788 The placenta is a key source of oxytocinase during gestation and produces increasing amounts of the enzyme in response to increasing levels of oxytocin produced by the mother.A229058,A229063 Oxytocinase activity is also expressed in mammary glands, heart, kidney, and the small intestine.A228593 Lower levels of activity can be found in the brain, spleen, liver, skeletal muscle, testes, and colon.A228593 The level of oxytocin degradation is negligible in non-pregnant women, men, and cord blood.L31788

Rute Eliminasi

The enzyme oxytocinase is largely responsible for the metabolism and regulation of oxytocin levels in pregnancy; only a small percentage of the neurohormone is excreted in the urine unchanged.L31433,L31788

Interaksi Obat

407 Data
Carboprost tromethamine Carboprost tromethamine may increase the uterotonic activities of Oxytocin.
Dinoprostone The risk or severity of adverse effects can be increased when Dinoprostone is combined with Oxytocin.
Misoprostol The risk or severity of adverse effects can be increased when Misoprostol is combined with Oxytocin.
Leuprolide The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Leuprolide.
Goserelin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Goserelin.
Erythromycin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Erythromycin.
Azithromycin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Azithromycin.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moxifloxacin.
Ranolazine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ranolazine.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulfisoxazole.
Amitriptyline The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amitriptyline.
Methadone The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methadone.
Diltiazem The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Diltiazem.
Clozapine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clozapine.
Sulpiride The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulpiride.
Nimodipine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nimodipine.
Promazine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Promazine.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prochlorperazine.
Droperidol The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Droperidol.
Imipramine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Imipramine.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorpromazine.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Oxytocin.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ciprofloxacin.
Fluorouracil The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluorouracil.
Perflutren The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Perflutren.
Cinnarizine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cinnarizine.
Atropine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atropine.
Chloroquine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chloroquine.
Efavirenz The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Efavirenz.
Adenosine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Adenosine.
Pentamidine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pentamidine.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gadobenic acid.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Carbinoxamine.
Dolasetron The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dolasetron.
Roxithromycin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Roxithromycin.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nalidixic acid.
Cinoxacin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cinoxacin.
Loperamide The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Loperamide.
Granisetron The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Granisetron.
Ondansetron The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ondansetron.
Levosimendan The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levosimendan.
Mesoridazine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mesoridazine.
Desloratadine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desloratadine.
Telithromycin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Telithromycin.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lomefloxacin.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dimenhydrinate.
Primaquine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Primaquine.
Papaverine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Papaverine.
Chlorpheniramine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorpheniramine.
Nifedipine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nifedipine.
Levofloxacin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levofloxacin.
Gemifloxacin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gemifloxacin.
Ofloxacin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ofloxacin.
Propafenone The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propafenone.
Flecainide The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flecainide.
Clarithromycin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clarithromycin.
Levacetylmethadol The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levacetylmethadol.
Saquinavir The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Saquinavir.
Clomipramine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clomipramine.
Mibefradil The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mibefradil.
Probucol The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Probucol.
Aceprometazine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aceprometazine.
Prenylamine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prenylamine.
Fluspirilene The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluspirilene.
Lofexidine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lofexidine.
Azimilide The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Azimilide.
Pracinostat The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pracinostat.
Technetium Tc-99m ciprofloxacin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Technetium Tc-99m ciprofloxacin.
Garenoxacin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Garenoxacin.
Tedisamil The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tedisamil.
Tucidinostat The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tucidinostat.
Telavancin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Telavancin.
Pazopanib The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pazopanib.
Nemonoxacin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nemonoxacin.
Panobinostat The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Panobinostat.
Nilvadipine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nilvadipine.
Antazoline The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Antazoline.
Crizotinib The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Crizotinib.
Bedaquiline The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bedaquiline.
Fendiline The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fendiline.
Eperisone The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eperisone.
Butriptyline The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Butriptyline.
Ceritinib The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ceritinib.
Lenvatinib The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lenvatinib.
Melperone The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Melperone.
Benidipine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Benidipine.
Dexchlorpheniramine maleate The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexchlorpheniramine maleate.
Amifampridine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amifampridine.
Mocetinostat The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mocetinostat.
Entinostat The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Entinostat.
Gilteritinib The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gilteritinib.
CUDC-101 The risk or severity of QTc prolongation can be increased when Oxytocin is combined with CUDC-101.
Simendan The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Simendan.
Ricolinostat The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ricolinostat.
Mizolastine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mizolastine.
Abexinostat The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Abexinostat.
Oxatomide The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxatomide.
Sitafloxacin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sitafloxacin.
Sultopride The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sultopride.
Otilonium The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Otilonium.

Target Protein

Oxytocin receptor OXTR
Vasopressin V1b receptor AVPR1B
Vasopressin V2 receptor AVPR2
Vasopressin V1a receptor AVPR1A

Referensi & Sumber

Synthesis reference: Kerstin Uvnas-Moberg, Thomas Lundeberg, "Use of substances having oxytocin activity for preparation of medicaments for wound healing." U.S. Patent US6262021, issued August, 1988.
Artikel (PubMed)
  • PMID: 15931222
    Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E: Oxytocin increases trust in humans. Nature. 2005 Jun 2;435(7042):673-6.
  • PMID: 16249339
    Takayanagi Y, Yoshida M, Bielsky IF, Ross HE, Kawamata M, Onaka T, Yanagisawa T, Kimura T, Matzuk MM, Young LJ, Nishimori K: Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16096-101. Epub 2005 Oct 25.
  • PMID: 3782434
    Carmichael MS, Humbert R, Dixen J, Palmisano G, Greenleaf W, Davidson JM: Plasma oxytocin increases in the human sexual response. J Clin Endocrinol Metab. 1987 Jan;64(1):27-31.
  • PMID: 12093924
    Paquin J, Danalache BA, Jankowski M, McCann SM, Gutkowska J: Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9550-5. Epub 2002 Jul 1.
  • PMID: 15316117
    Jankowski M, Danalache B, Wang D, Bhat P, Hajjar F, Marcinkiewicz M, Paquin J, McCann SM, Gutkowska J: Oxytocin in cardiac ontogeny. Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13074-9. Epub 2004 Aug 17.
  • PMID: 24888645
    Arrowsmith S, Wray S: Oxytocin: its mechanism of action and receptor signalling in the myometrium. J Neuroendocrinol. 2014 Jun;26(6):356-69. doi: 10.1111/jne.12154.
  • PMID: 30253045
    Ding C, Leow MK, Magkos F: Oxytocin in metabolic homeostasis: implications for obesity and diabetes management. Obes Rev. 2019 Jan;20(1):22-40. doi: 10.1111/obr.12757. Epub 2018 Sep 25.
  • PMID: 32912963
    Carter CS, Kenkel WM, MacLean EL, Wilson SR, Perkeybile AM, Yee JR, Ferris CF, Nazarloo HP, Porges SW, Davis JM, Connelly JJ, Kingsbury MA: Is Oxytocin "Nature's Medicine"? Pharmacol Rev. 2020 Oct;72(4):829-861. doi: 10.1124/pr.120.019398.
Menampilkan 8 dari 21 artikel.

Contoh Produk & Brand

Produk: 45 • International brands: 0
Produk
  • Bakumokon 5% Minoxidil
    Liquid • - • Topical • US • OTC
  • Bakumokon 7% Minoxidil Sulfate
    Liquid • - • Topical • US • OTC
  • Oxytocin
    Injection • 10 [USP'U]/1mL • Intravenous • US • Generic • Approved
  • Oxytocin
    Injection • 100 [USP'U]/10mL • Intravenous • US • Generic • Approved
  • Oxytocin
    Injection, solution • 10 [USP'U]/500mL • Intravenous • US
  • Oxytocin
    Injection, solution • 10 [USP'U]/500mL • Intravenous • US
  • Oxytocin
    Injection • 10 [USP'U]/1mL • Intramuscular; Intravenous • US • Generic • Approved
  • Oxytocin
    Injection • 100 [USP'U]/10mL • Intramuscular; Intravascular • US • Generic • Approved
Menampilkan 8 dari 45 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul